Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,680 result(s) found for: Cell therapy. Displaying page 1 of 284.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-003511-20 Sponsor Protocol Number: 201700599 Start Date*: 2019-01-30
    Sponsor Name:HOVON Foundation
    Full Title: Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment
    Medical condition: Diffuse large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003657-26 Sponsor Protocol Number: ARD10248 Start Date*: 2012-01-16
    Sponsor Name:sanofi aventis recherche et développement
    Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005889-40 Sponsor Protocol Number: ABR-15108 Start Date*: 2007-08-14
    Sponsor Name:Academic Medical Centre
    Full Title: N-Acetylcysteine for Treatment of Sickle Cell Disease
    Medical condition: Patients homozygous for sickle cell disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040644 Sickle cell disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003729-18 Sponsor Protocol Number: LENALIDOMIDEand DLBCL Start Date*: 2008-09-25
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: A phase II trial to evaluate the safety and activity of single-agent lenalidomide given as maintenance therapy after response to second-line therapy in patients with relapsed diffuse large B cell l...
    Medical condition: patients affected by diffused linfoma with big cells
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-005245-37 Sponsor Protocol Number: M06-880 Start Date*: 2008-04-17
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: An Open-Label, Randomized, Phase 2 Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Medical condition: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061873 Non-small cell lung cancer LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029514 Non-small cell lung cancer NOS LLT
    9.1 10029515 Non-small cell lung cancer recurrent LLT
    9.1 10029516 Non-small cell lung cancer stage 0 LLT
    9.1 10029517 Non-small cell lung cancer stage I LLT
    9.1 10029518 Non-small cell lung cancer stage II LLT
    9.1 10029519 Non-small cell lung cancer stage III LLT
    9.1 10029520 Non-small cell lung cancer stage IIIA LLT
    9.1 10029521 Non-small cell lung cancer stage IIIB LLT
    9.1 10029522 Non-small cell lung cancer stage IV LLT
    9.1 10059515 Non-small cell lung cancer metastatic LLT
    9.1 10029515 Non-small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003079-32 Sponsor Protocol Number: CC-5013-CLL-008 Start Date*: 2009-06-19
    Sponsor Name:Celgene Corporation
    Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA...
    Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000473-23 Sponsor Protocol Number: RETRY Start Date*: 2012-05-29
    Sponsor Name:GIOM - Gruppo Italiano Oncologia Nefrologica
    Full Title: PHASE II STUDY OF SUNITINIB AS RECHALLENGE THIRD-LINE THERAPY IN METASTATIC RENAL CANCER
    Medical condition: Metastatic renal cancer thrid-line therapy already treated in fist-line therapy with Sunitinib.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009251 Clear cell carcinoma of the kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005942-22 Sponsor Protocol Number: MK8669-021 Start Date*: 2009-01-15
    Sponsor Name:MERCK & CO., INC.
    Full Title: A Randomized Discontinuation Phase II Trial of Deforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations.
    Medical condition: Non-Small Cell Lung Cancer (NSCLC) Patients with KRAS Mutations
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004305-24 Sponsor Protocol Number: BCCItraconazole Start Date*: 2012-04-18
    Sponsor Name:Med Uni Graz, Univ. Klinik Dermatologie,Abteilung für Allgemeine Dermatologie
    Full Title: Inhibition of the Hedgehog Pathway in Basal Cell Carcinomas of Patients treated with Itraconazole for Onychomycosis
    Medical condition: Basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    14.1 10042613 - Surgical and medical procedures 10004148 Basal cell carcinoma excision LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003796-20 Sponsor Protocol Number: HOVON 77 Start Date*: 2007-01-03
    Sponsor Name:HOVON Foundation
    Full Title: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission f...
    Medical condition: patients with diffuse Large B-Cell lymphoma, CD20-positive
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001491-20 Sponsor Protocol Number: STORM-2011 Start Date*: 2012-10-04
    Sponsor Name:Ruprecht-Karls University Heidelberg, Medical Faculty
    Full Title: A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP f...
    Medical condition: Diffuse large B-cell lymphoma with documented relapse or progression following at least one but a maximum of two prior treatments, aged older than 18 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004943 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-002605-35 Sponsor Protocol Number: HO151 Start Date*: 2018-08-28
    Sponsor Name:HOVON Foundation
    Full Title: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
    Medical condition: Diffuse large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004851-39 Sponsor Protocol Number: 109/2006/U/Sper Start Date*: 2006-10-03
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DI...
    Medical condition: DIFFUSE LARGE BCELL LYMPHOMA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012818 Diffuse large B-cell lymphoma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007696-16 Sponsor Protocol Number: TOGA 0601 Start Date*: 2008-06-02
    Sponsor Name:TOGA Thoracic Oncology Group Antwerp
    Full Title: Low molecular weight heparin in advanced non small cell lung cancer (NSCLC): a randomized open label phase III study evaluating the effect of enoxaparin (Clexane) on survival and symptom control in...
    Medical condition: Non Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025054 Lung cancer non-small cell stage IIIB LLT
    9.1 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022812-37 Sponsor Protocol Number: ORH/PID/6265 Start Date*: 2011-06-07
    Sponsor Name:Oxford University Hospitals NHS Trust
    Full Title: A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma
    Medical condition: Diffuse Large B-cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000092-33 Sponsor Protocol Number: PDTA02_24.05.2013 Start Date*: 2013-10-23
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik.f.Dermatologie
    Full Title: Enhanced efficacy of photodynamic therapy in combination with 5% imiquimod -a randomised, prospective, observer-blinded study in patients with non melanoma skin cancer
    Medical condition: non melanoma skin cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003122-16 Sponsor Protocol Number: R2810-ONC-1620 Start Date*: 2017-09-28
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1, IN PATIENTS WITH ADVANCED BASAL CELL CARCINOMA WHO EXPERIENCED PROGRESSION OF DISEASE ON HEDGEHOG PATHWAY INHIB...
    Medical condition: Metastatic basal cell carcinoma or unresectable locally advanced basal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) AT (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004722-27 Sponsor Protocol Number: ICT-BEM-2004-01 Start Date*: 2005-05-12
    Sponsor Name:Instituto Científico y Tecnológico de Navarra, S.A.
    Full Title: Randomised, open, multicenter, sequential trial assessing the safety and efficacy of bemiparin on the response to the treatment in patients diagnosed with localized small cell carcinoma of the lung.
    Medical condition: Small cell carcionoma of the lung medDRA CLASSIFICATION CODE: PT 10041071
    Disease: Version SOC Term Classification Code Term Level
    4.0 10041071 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003560-31 Sponsor Protocol Number: UKM18_0021 Start Date*: 2020-01-29
    Sponsor Name:Universitätsklinikum Münster
    Full Title: A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
    Medical condition: diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 00:20:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA